Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT01414153 is registered in ClinicalTrials.gov with Lpath, Inc. as lead sponsor.

NCT NCT01414153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01414153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Lead sponsor
Lpath, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
June 30, 2015
Enrollment
158 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

exudative age-related macular degeneration